Fluorescent microscopy and bioluminescence imaging revealed significantly enhanced tumor cell killing in the group treated with iMRAS conjugated with CD1d/αGC+IL-15Tx compared to other conjugation strategies, including control and CD1d-only treatments (Fig. 2b, c). The gene discussed is CD1D; the disease is neoplasm.